Skip to content

Effect of thoracic paravertebral block anesthesia on postoperative recovery quality, immune function and prognosis of breast cancer patients

Effect of thoracic paravertebral block anesthesia on postoperative recovery quality, immune function and prognosis of breast cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049641
Enrollment
Unknown
Registered
2021-08-07
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

group A:General anesthesia (intravenous induction + inhalation maintenance)
group B :General anesthesia + thoracic paravertebral nerve block

Sponsors

Cancer Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients who voluntarily participated in the study and signed a written informed consent; 2. Females aged 18-60 years when signing the informed consent form; 3. Histologically or cytologically confirmed breast adenocarcinoma; 4. It is planned to undergo unilateral modified radical surgery for breast cancer under elective general anesthesia; 5. American society of anesthesiologists (ASA) grade I or II; 6. Asian race.

Exclusion criteria

Exclusion criteria: 1. Patients with inflammatory diseases; 2. Patients who have received surgical treatment within the past 30 days; 3. Pregnant patients; 4. Patients with liver and kidney diseases; 5. Long-term drinking, long-term use of psychotropic drugs such as sedatives or antidepressants; 6. There are contraindications for paravertebral nerve block, including severe abnormal coagulation function, infection at the puncture site, trauma or history of spinal surgery; 7. Unable to cooperate with the research for any reason, such as the following situations: difficulty in language comprehension, mental illness, inability to visit the hospital for follow-up, etc.; 8. Taking other experimental drugs or participating in other clinical trials within 3 months before being enrolled in the study; 9. Preoperative radiotherapy or chemotherapy; 10. Other situations that the investigator thinks should not be included in this trial.

Design outcomes

Primary

MeasureTime frame
VEGF-C;TGF-ß;Myeloid-derived suppressor cells;Neutrophil-lymphocyte ratio (NLR);Immune related cytokines;Pain score VAS;Recurrence-free survival ;Overall survival,OS;

Secondary

MeasureTime frame
Intraoperative anesthetic maintenance dose;Hemodynamic indexes;Recovery room residence time;QoR-40 score;Complications;Anesthesia satisfaction;

Countries

China

Contacts

Public ContactYan Tao

Cancer Hospital, Chinese Academy of Medical Sciences

blizzardyt@163.com+86 13522553375

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026